razoxane has been researched along with Soft Tissue Neoplasms in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (55.56) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eiter, H; Rhomberg, W; Saely, CH; Schmid, F | 1 |
| Liu, TF; Zhang, XF; Zhang, ZY | 1 |
| Ash, A; Borden, EC; Enterline, HT; Falkson, G; Laucius, JF; Lerner, H; Paul, AR; Rosenbaum, C | 1 |
| Andrich, MP; Avila, N; Balis, FM; Berg, SL; Chen, CC; Dilsizian, V; Horowitz, ME; Jarosinski, P; Poplack, DG; Venzon, D; Weaver-McClure, L; Wexler, LH | 1 |
| Gefeller, D; Hassenstein, EO; Rhomberg, W | 1 |
| Bates, T; Hellmann, K; Newton, KA; Ryall, RD | 1 |
| Gefeller, D; Hassenstein, E; Mesche, E; Rhomberg, W | 1 |
| Hellmann, K; James, SE; Jones, S; Macdonald, E; Newton, KA; Ryall, RD | 1 |
| Krawczyk, J; Svoboda, VH | 1 |
5 trial(s) available for razoxane and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Combined vindesine and razoxane shows antimetastatic activity in advanced soft tissue sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Humans; Neoplasm Metastasis; Pilot Projects; Radiotherapy; Razoxane; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome; Vindesine | 2008 |
Preliminary report on AT1727 as a potential radiosensitizer.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Humans; Lung Neoplasms; Neoplasms; Piperazines; Radiation-Sensitizing Agents; Random Allocation; Razoxane; Sarcoma; Soft Tissue Neoplasms | 1984 |
Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Cardiovascular Agents; Child; Doxorubicin; Female; Heart; Humans; Injections, Intravenous; Male; Neuroectodermal Tumors, Primitive, Peripheral; Razoxane; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Soft Tissue Neoplasms; Stroke Volume; Survival Rate; Transaminases | 1996 |
Radiotherapy vs. radiotherapy and razoxane in the treatment of soft tissue sarcomas: final results of a randomized study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Prospective Studies; Radiation-Sensitizing Agents; Razoxane; Sarcoma; Soft Tissue Neoplasms | 1996 |
[Clinical experiences with radiotherapy and ICRF 159 in sarcomas].
Topics: Adult; Aged; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Piperazines; Radiotherapy Dosage; Random Allocation; Razoxane; Sarcoma; Soft Tissue Neoplasms | 1978 |
4 other study(ies) available for razoxane and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Drug Evaluation; Female; Humans; Male; Maytansine; Mesothelioma; Middle Aged; Mitolactol; Osteosarcoma; Oxazines; Piperazines; Prognosis; Random Allocation; Razoxane; Sarcoma; Soft Tissue Neoplasms | 1982 |
Combination of radiotherapy and razoxane (ICRF 159) for chondrosarcoma.
Topics: Adult; Aged; Bone Neoplasms; Chondrosarcoma; Female; Humans; Male; Middle Aged; Piperazines; Radiotherapy, High-Energy; Razoxane; Remission, Spontaneous; Soft Tissue Neoplasms; Time Factors | 1979 |
Comparison of radiotherapy with and without razoxane (ICRF 159) in the treatment of soft tissue sarcomas.
Topics: Adult; Aged; Female; Humans; Leukopenia; Male; Middle Aged; Piperazines; Radiotherapy, High-Energy; Razoxane; Recurrence; Remission, Spontaneous; Sarcoma; Soft Tissue Neoplasms | 1978 |
Management of soft tissue sarcomas in Portsmouth 1965-1985.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Cobalt Radioisotopes; Combined Modality Therapy; England; Female; Humans; Male; Middle Aged; Radiotherapy Dosage; Radiotherapy, High-Energy; Razoxane; Remission Induction; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Survival Rate | 1991 |